Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q2 revenue rose 30% to $1.7 billion and GAAP EPS increased 144% to $2.05. Recent FDA approval of a TEVIMBRA-based regimen and positive Phase 3 MANGROVE results provide fresh catalysts; shares were up 15.7% through August 27.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Position ⢠Margin Expansion ⢠Elevated Valuation ONC offers strong liquidity, improving margins, and solid free cash flow, but high valuation multiples, modest ROE, and large retained losses warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Persistent downtrend ⢠Failed rebound ⢠Key support test Support Level: $346.50â$341.80 Resistance Level: $354.00â$362.00 ONC remains technically weak over the last month, with support at $346.50â$341.80 and resistance at $354.00â$362.00; a break below support would be bearish, while reclaiming $354.00 would improve the outlook.
Sentiment & News
Key News Insights: ⢠FDA regimen approval ⢠Positive Phase 3 ⢠Policy access deal BeOne's FDA approval and positive Phase 3 data strengthen its growth outlook, though policy and insider-selling developments warrant monitoring.
AI Summary
ONC has evolved into a cash-generative oncology platform with BRUKINSA expansion and TEVIMBRA/ZIIHERA launches offering credible upside, but at 56.8x earnings investors should own it only if they expect sustained margin gains and successful clinical-commercial execution to validate its premium valuation.
Description
BeOne Medicines, formerly BeiGene, is a global oncology company that discovers, develops and commercializes cancer therapies. Headquartered in Cambridge, Massachusetts and redomiciled to Basel in 2025, the firm operates in over 45 countries and maintains a pipeline across hematologic malignancies and solid tumors sourced from internal R&D and external collaborations. Its marketed medicines include the PD-1 antibody Tevimbra (tislelizumab) and the BTK inhibitor Brukinsa (zanubrutinib), the latter generating more than $1.3 billion in annual sales and approved in major markets.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 27 | Sep 3 | ONC | BeOne Medicines Ltd. | Q2 revenue rose 30% to $1.7 billion and GAAP EPS increased 144% to $2.05. Recent FDA approval of a TEVIMBRA-based regimen and positive Phase 3 MANGROVE results provide fresh catalysts; shares were up 15.7% through August 27. | Closed | -2.6% |